CA125/CEA比值及超声参数在鉴别多房和多房实性卵巢肿块转移瘤中的作用
回顾性分析三个超声中心350例卵巢肿瘤与46例卵巢转移瘤患者,比较多房(≥5房)及多房实性肿块的超声特征及CA125/CEA比值。卵巢肿瘤最大径小于转移瘤(97 mm vs 146 mm,P<0.0001),囊肿>10房者比例更低(18.9% vs 54.3%,P<0.0001)。CEA与CA125/CEA比值鉴别卵巢肿瘤与转移瘤的AUC分别为0.791和0.758,差异无统计学意义,作者认为该形态亚组中单用CEA即可鉴别。
要点
- 多房或多房实性卵巢肿块中,转移瘤最大径大于卵巢肿瘤(146 mm vs 97 mm,P<0.0001)。
- 转移瘤中囊肿>10房者占54.3%,高于卵巢肿瘤的18.9%(P<0.0001)。
- CEA与CA125/CEA比值鉴别能力无显著差异,该形态亚组单用CEA即可。
核心结论
- 在多房和多房实性卵巢肿块中,CA125/CEA比值与单用CEA鉴别卵巢肿瘤(含良性和恶性)与卵巢转移瘤的能力无显著差异,因此该形态亚组中单用CEA即可鉴别。
研究设计与样本
- 回顾性研究,从三个超声中心纳入超声检查后3个月内手术且诊断时有CEA和CA125肿瘤标志物的多房(≥5房)或多房实性卵巢肿块患者,共350例(88.4%)卵巢肿瘤和46例(11.6%)卵巢转移瘤,肿块按IOTA术语描述。
关键影像表现/征象
- 卵巢肿瘤最大径中位数97 mm(范围20-387 mm),小于转移瘤的146 mm(范围43-259 mm),P<0.0001;囊肿>10房者卵巢肿瘤占18.9%,转移瘤占54.3%,P<0.0001。
诊断标准与关键数值
- CEA鉴别卵巢肿瘤与卵巢转移瘤的最佳截断值为2.33 ng/mL,AUC 0.791(95%CI 0.711-0.870),准确率73.7%,敏感度73.1%,特异度78.3%,阳性预测值96.2%,阴性预测值27.7%。
临床应用与阅片要点
- 对多房(≥5房)或多房实性卵巢肿块,可测量最大径并计数囊肿房数辅助判断;CEA截断值2.33 ng/mL及CA125/CEA截断值11.92可用于鉴别卵巢肿瘤与转移瘤。
局限性
- 本研究为回顾性研究。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate ultrasound features and the best cut-off value of the cancer antigen 125/carcinoembryonic antigen (CA125/CEA) ratio to discriminate ovarian metastases from benign and primary malignant ovarian neoplasms in two selected groups of morphological ovarian masses, namely multilocular masses with five or more locules and multilocular-solid masses.
METHODS: Patients with multilocular (five or more locules) or multilocular-solid ovarian masses, operated on within 3 months of ultrasound examination, and with tumor markers (CEA and CA125) available at diagnosis, were identified retrospectively from three ultrasound centers. The masses were described using the International Ovarian Tumor Analysis (IOTA) terminology. Ultrasound and clinical characteristics were compared between those with an ovarian neoplasm (including benign and primary malignant neoplasms) and those with an ovarian metastasis. Receiver-operating characteristics curve (ROC) analysis was used to evaluate the ability of CA125, CEA and CA125/CEA to differentiate between ovarian neoplasms and ovarian metastases, and their predictive performance was assessed.
RESULTS: In total, 350 (88.4%) patients with an ovarian neoplasm (including 99 benign, 43 borderline and 197 primary epithelial ovarian carcinomas, seven malignant rare tumors and four other types of invasive ovarian tumor) and 46 (11.6%) patients with an ovarian metastasis were analyzed. On ultrasound examination, ovarian neoplasms were smaller than ovarian metastases (median largest diameter, 97 (range, 20-387) mm vs 146 (range, 43-259) mm, respectively; P < 0.0001) and presented with a lower number of cysts with > 10 locules (18.9% vs 54.3%; P < 0.0001). ROC curve analysis showed that the best cut-off value of CEA for distinguishing between ovarian neoplasms and ovarian metastases was 2.33 ng/mL. The predictive performance of this CEA cut-off value was: area under the curve (AUC), 0.791 (95% CI, 0.711-0.870); accuracy, 73.7%; sensitivity, 73.1%; specificity, 78.3%; positive predictive value (PPV), 96.2%; and negative predictive value (NPV), 27.7%. The best cut-off value of CA125/CEA for distinguishing between ovarian neoplasms and ovarian metastases was 11.92. The predictive performance of this CA125/CEA cut-off value was: AUC, 0.758 (95% CI, 0.683-0.833); accuracy, 79.8%; sensitivity, 82.3%; specificity, 60.9%; PPV, 94.1%; and NPV, 31.1%.
CONCLUSIONS: CA125/CEA ratio and CEA alone did not show any significant difference in their ability to distinguish between ovarian neoplasms (including benign and malignant) and ovarian metastases in masses with multilocular and those with multilocular-solid morphology. Therefore, in this morphological subgroup of ovarian masses, CEA alone is sufficient to differentiate between ovarian neoplasms and ovarian metastases. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Moro F, Pasciuto T, Djokovic D, et al. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol. 2019. PMID: 29978587. doi:10.1002/uog.19174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。